8-K: Theriva Biologics Advances VCN-01 in Pancreatic Cancer

Theriva Biologics, Inc. presented updated clinical data for its lead oncolytic virus candidate, VCN-01, showing promising results in metastatic pancreatic cancer and retinoblastoma.

Summary

• Theriva Biologics is developing unique oncolytic virus therapies for multiple solid tumors, with VCN-01 as its lead candidate.
• VCN-01 is preparing for Phase 3 clinical trials in first-line metastatic pancreatic cancer and planning Phase 2/3 in retinoblastoma.
• Phase 1 clinical data for VCN-01 supports its potential in additional indications, including colorectal cancer and head-and-neck squamous cell carcinoma.
• The company's VCN-X innovative discovery engine is actively developing a distinct pipeline of next-generation oncolytic viruses.
• Theriva Biologics is actively seeking financing and/or partnerships to execute planned pivotal trial programs.
• The VIRAGE Phase 2b trial for VCN-01 in pancreatic cancer demonstrated increased overall survival (OS) and progression-free survival (PFS) in the VCN-01 plus standard-of-care (SoC) group compared to SoC alone.
• Patients receiving two doses of VCN-01 in the VIRAGE trial showed a greater survival benefit, with a median OS of 14.8 months (HR 0.44) compared to 11.6 months for SoC in a subgroup analysis.
• Duration of response (DoR) doubled in the VCN-01+SoC arm, reaching 11.2 months compared to 5.4 months for SoC.
• VCN-01 exhibited an acceptable adverse event profile, consistent with prior clinical trials.
• Regulatory agreement for the Phase 3 design is being pursued, with positive scientific advice from the European Medicines Agency (EMA) and an FDA End-of-Phase 2 meeting anticipated in Q1 2026.
• Additional clinical activities include a potential Phase 1b study in PDAC to explore more frequent VCN-01 dosing and a potential pivotal trial in retinoblastoma.

Sentiment

Score: 7

Explanation: The clinical data for VCN-01, particularly in pancreatic cancer, shows promising efficacy and safety, with favorable comparisons to industry benchmarks. Regulatory progress is also positive. However, the explicit need for financing for pivotal trials introduces a significant element of uncertainty and risk, tempering the overall positive sentiment.

Positives

• VCN-01, the lead candidate, is preparing for Phase 3 clinical trials in first-line metastatic pancreatic cancer.
• VIRAGE Phase 2b clinical data showed increased overall survival (OS), progression-free survival (PFS), and duration of response (DoR) in the VCN-01 plus standard-of-care (SoC) treatment group compared to SoC alone.
• A subgroup of patients receiving two doses of VCN-01 demonstrated a median OS of 14.8 months (HR 0.44) compared to 11.6 months for SoC, and a median PFS of 11.2 months (HR 0.48) compared to 7.4 months for SoC.
• Duration of response doubled in the VCN-01+SoC arm to 11.2 months compared to 5.4 months for SoC.
• VCN-01 demonstrated an acceptable adverse event profile, with AEs being less frequent and of reduced grade after the second dose.
• Positive Scientific Advice was received from the European Medicines Agency (EMA) for the proposed Phase 3 trial design, indicating a single successful study could support marketing authorization.
• VCN-01 has Orphan Drug Designation (US, EU) and Fast Track Designation (US) for pancreatic ductal adenocarcinoma (PDAC).
• The retinoblastoma program has Orphan Drug Designation (US, EU) and Rare Pediatric Disease Designation (US), potentially enabling access to a monetizable Priority Review Voucher.
• Cash of $15.5M was reported as of November 10, 2025, with a projected cash runway into Q1 2027.
• VCN-01 showed promising antitumor activity in retinoblastoma, avoiding enucleation in 2 out of 6 evaluable patients.
• VCN-01 in combination with durvalumab in head and neck squamous cell carcinoma (HNSCC) showed higher than expected survival despite previous anti-PD(L)1 failure, with survival correlated to PD-L1 upregulation after VCN-01 treatment.

Negatives

• The company is seeking financing and/or partnerships to execute planned pivotal trial programs, indicating a potential funding gap for future large-scale trials.
• Pancreatic cancer remains a highly fatal cancer with a median survival of 8-11 months for metastatic disease, highlighting the significant challenge.
• The main analysis for overall survival in the VIRAGE trial showed a p-value of 0.0546, which is just above the conventional 0.05 significance threshold, though the subgroup analysis was statistically significant.

Risks

• Ability to enroll patients as planned and reach clinical trial milestones when anticipated.
• Ability to complete clinical trials on time and achieve desired results and benefits.
• Product candidates demonstrating safety and effectiveness, including positive clinical data that demonstrates VCN-01 may lead to improved clinical outcomes for patients.
• Ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements.
• Regulatory limitations relating to the ability to promote or commercialize product candidates for specific indications.
• Acceptance of product candidates in the marketplace and the successful development, marketing, or sale of products.
• Developments by competitors that render such products obsolete or non-competitive.
• Ability to maintain license agreements.
• Continued maintenance and growth of the patent estate.
• Ability to continue to remain well financed.

Future Outlook

The company plans to prepare for a Phase 3 clinical trial for VCN-01 in first-line metastatic pancreatic cancer and a Phase 2/3 trial in retinoblastoma. They anticipate an FDA End-of-Phase 2 meeting in Q1 2026 to review the proposed Phase 3 design. A potential Phase 1b study in PDAC is being considered to explore more frequent VCN-01 dosing. The VCN-X discovery engine continues to advance new oncolytic virus candidates, including VCN-11 with Albumin Shield technology. The company is actively seeking financing and/or partnerships to fund these pivotal trial programs.

Management Comments

• Oncolytic viruses (OVs) are promising cancer therapeutics.
• VCN-01 has multiple potential value opportunities.
• Regulatory status expected to facilitate VCN-01 development.
• The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
• Based on Managements current beliefs and expectations (regarding pipeline status).

Industry Context

The pancreatic cancer treatment market is estimated at ~$2.9 billion in 2024 and projected to grow to ~$6.0 billion by 2030, indicating a significant and growing need for effective therapies. VCN-01 is positioned as a uniquely engineered human adenovirus designed to overcome key oncolytic virus challenges, including systemic delivery, selective tumor replication, and stroma degradation, which are critical for treating solid tumors like pancreatic cancer. The company compares VCN-01 to other oncolytic viruses in development from Replimune, Oncolytics Biotech, Genelux, and CG Oncology, highlighting its distinct features like PH20 hyaluronidase expression for stroma degradation.

Comparison to Industry Standards

• The VIRAGE Phase 2b trial results for VCN-01 plus gemcitabine/nab-paclitaxel showed better hazard ratios for overall survival (HR 0.57) and progression-free survival (HR 0.55) compared to the NALIRIFOX Phase 3 trial (HR 0.83 for OS, HR 0.69 for PFS) which used leucovorin+5-FU+liposomal irinotecan+oxaliplatin.
• VCN-01's median overall survival of 10.8 months (main analysis) and 14.8 months (two doses subgroup) compares favorably to NALIRIFOX's 11.1 months and gemcitabine/nab-paclitaxel's 9.2 months in the NAPOLI 3 trial.
• VCN-01's median progression-free survival of 7.0 months (main analysis) and 11.2 months (two doses subgroup) compares favorably to NALIRIFOX's 7.4 months and gemcitabine/nab-paclitaxel's 5.6 months in the NAPOLI 3 trial.
• VCN-01 is differentiated from other oncolytic viruses like Replimune's RP1/RP2 (Herpes Simplex), Oncolytics Biotech's Pelareorep (Reovirus), Genelux's Olvi-Vec (Vaccinia), and CG Oncology's Cretostimogene grenadenorepvec (Adenovirus 5) by its specific engineering for selective replication, systemic administration, and PH20 hyaluronidase expression for stroma degradation.

Stakeholder Impact

• Shareholders: Positive clinical data could increase share value, but the need for capital raises introduces dilution risk.
• Patients: Promising new treatment options for highly fatal cancers like pancreatic cancer and rare pediatric diseases like retinoblastoma.
• Employees: Continued development and potential commercialization could lead to job stability and growth.
• Creditors/Investors: The need for financing indicates potential future investment opportunities or risks depending on the terms.

Next Steps

• Anticipated FDA End-of-Phase 2 Meeting in Q1 2026 to review proposed Phase 3 trial design for VCN-01 in pancreatic cancer.
• Potential Phase 1b study in PDAC to explore more frequent VCN-01 dosing (q2 months).
• Planning a potential pivotal trial in retinoblastoma (intravitreal VCN-01 plus topotecan).
• Submission of VIRAGE AACR Presentation abstract.
• VCN-12 candidate (next generation OV) development.
• VCN-01 CMC Scale-up (contingent on funding).
• Potential out-license of legacy asset SYN-004.
• Initiate final Phase 1b/2a cohort for SYN-004 in allo-HCT (contingent on investigator grant funding).

Key Dates

Recommendation

While the clinical data for VCN-01 in pancreatic cancer is encouraging and shows superior hazard ratios compared to a competitor, the explicit need for external financing and partnerships to advance pivotal trials presents a significant funding risk. The projected cash runway into Q1 2027 suggests a near-term need for capital. Investors should hold to monitor the progress of securing funding and the outcomes of regulatory meetings, as these will be critical determinants of the company's ability to execute its strategic plans and realize the potential of its pipeline.

Keywords

Theriva Biologics, VCN-01, oncolytic virus, pancreatic cancer, retinoblastoma, head and neck cancer, solid tumors, VIRAGE trial, Phase 3, clinical trial, oncology, immunotherapy, SEC filing, 8-K, TOVX, biopharmaceutical, cancer therapy, hyaluronidase, stroma degradation